

Press Release

Net Revenues of Indoco Remedies rise by 14% at ₹ 212 Crores

Mumbai, May 27, 2015: During the quarter under review, the net revenues of Indoco Remedies Ltd grew by 13.8 % to ₹ 211.6 crores as against ₹ 185.9 crores for the same period last year. The Profit After Tax (PAT) is at ₹ 18.7 crores compared to ₹ 18.5 crores in the corresponding quarter last year.

The Board has recommended a dividend of 80% i.e. ₹ 1.60 per equity share.

The Company's domestic formulation business has introduced two new products in the fourth quarter, both in anti-infective segment taking the tally of new products launched to 19 for the year. For the US markets, the Company has 50 ANDAs, through partners and our own, at various stages, including 7 approvals, 18 pending for approvals and 25 under development.

Commenting on the quarterly performance, Mr. Suresh G. Kare, Chairman, Indoco Remedies said, "Domestic business grew by 17% compared to same quarter last year and by 15% over last year. International formulation business grew by 10% compared to same quarter last year and by 26% over last year. The year was marked by the successfully launch of two ophthalmic products in the US, receipt of three tentative approvals for sterile products filed by its marketing partner and successful inspection of our Finished Dosages and API facilities by USFDA".

For the quarter ended March'15, the financials are as under:

(₹ in Crores)

Particulars	Jan-Mar 2015	Jan-Mar 2014	Growth %
Net Revenue	211.6	185.9	13.8
EBIDTA	37.3	32.9	13.5
Profit Before Tax	22.9	22.6	1.6
Profit After Tax	18.7	18.5	1.1
EPS (Face value ₹ 2/-)	2.03	2.01	

For the year ended March'15, the financials are as under:

(₹ in Crores)

Particulars	April-Mar 2015	April-Mar 2014	Growth %
Net Revenue	848.9	717.4	18.3
EBIDTA	165.2	120.1	37.6
Profit Before Tax	109.5	72.1	51.8
Profit After Tax	82.8	57.9	43.0
EPS (Face value ₹ 2/-)	8.99	6.28	

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 80 countries. Indoco, a USD 136 million Company, employs over 5500 people including 250 skilled scientists.

The Company has 8 manufacturing facilities, 5 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 50 million prescriptions annually from over 2,00,000 doctors in India. Indoco has 10 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, ATM, Oxipod, Cital, Sensoform, Cloben-G, Sensodent-KF, Karvol Plus, Glychek, Vepan, Tuspel Plus, Flamar, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Kailash Rajwadkar

Mobile: 9869333999 / 9869111687

E-mail: kailash.rajwadkar@gmail.com

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com